Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988638 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MAPT | |
| SCHEMBL1759061 | 0.75 | MAPT (0.39) | KDM5AALDH1A1CA9TSHRMAPT | |
| SCHEMBL28233971 | 0.73 | KIF11 (0.34) | MAPTMAPK1NPSR1 | |
| SCHEMBL19774962 | 0.73 | HDAC1 (0.32) | KDM5ATSHRMAPTMAPK1NPSR1 | |
| SCHEMBL1758506 | 0.72 | ALDH1A1 (0.54) | ALDH1A1TSHRMAPT | |
| SCHEMBL13723265 | 0.72 | ALDH1A1 (0.33) | KDM5AALDH1A1TSHRPABPC1 | |
| SCHEMBL14540950 | 0.72 | KDM5A (0.44) | KDM5AALDH1A1MAPT | |
| SCHEMBL5434561 | 0.72 | NPC1 (0.53) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL14706964 | 0.72 | ALDH1A1 (0.40) | KDM5AALDH1A1NPSR1 | |
| SCHEMBL3132943 | 0.72 | KMT2A (0.47) | KDM5AALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735425-B2 | Tetrahydroisoquinoline derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2256105-B1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| CN-103396379-A | 5, 6-difluoro-benzothiazole and preparation method thereof | UNIV SOUTH CHINA TECH | 2013-11-20 | — | — | CN | disclosed |
| WO-2011047323-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2256105-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DGAT1, DGAT2, DLAT | KDM5A 2330/4885ALDH1A1 789/4885CA12 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.